Kala Pharmaceuticals gets FDA OK for Eysuvis

Patients with signs and symptoms of dry eye disease will soon have a new treatment available.

The Food and Drug Administration has approved Kala Pharmaceuticals' Eysuvis (loteprednol etabonate ophthalmic suspension) in a dosage strength of 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.

“The FDA approval of Eysuvis as the first prescription therapy specifically developed to address the short-term treatment needs of people living with dry eye disease is a major accomplishment for Kala and an important moment for patients, who have been waiting for an FDA approved, safe, effective and fast-acting therapy,” said Mark Iwicki, chairman, president and CEO.